Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 117

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Inflammasomes in neurological disorders — mechanisms and therapeutic potential

Ravichandran, Kishore Aravind, Heneka, Michael T. · 2024 · Nature Reviews Neurology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-023-00915-x

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 237

  1. Deora, V. et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia 68, 407–421 (2020). · DOI · Paper page
  2. Guo, H., Callaway, J. B. & Ting, J. P.-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677–687 (2015). · DOI · Paper page
  3. Zheng, D., Liwinski, T. & Elinav, E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 6, 36 (2020). · DOI · Paper page
  4. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821–832 (2010). · DOI · Paper page
  5. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426 (2002). · DOI · Paper page
  6. Martinon, F., Agostini, L., Meylan, E. & Tschopp, J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 14, 1929–1934 (2004). · DOI · Paper page
  7. Grenier, J. M. et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF‐κB and caspase‐1. FEBS Lett. 530, 73–78 (2002). · DOI · Paper page
  8. Khare, S. et al. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 36, 464–476 (2012). · DOI · Paper page
  9. Wang, L. et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing. J. Biol. Chem. 277, 29874–29880 (2002). · DOI · Paper page
  10. Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596–600 (2011). · DOI · Paper page
  11. Unterholzner, L. et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 997–1004 (2010). · DOI · Paper page
  12. Chae, J. J. et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34, 755–768 (2011). · DOI · Paper page
  13. Robinson, K. S. et al. Diphtheria toxin activates ribotoxic stress and NLRP1 inflammasome-driven pyroptosis. J. Exp. Med. 220, e20230105 (2023). · DOI
  14. Mangan, M. S. J. et al. Transcriptional licensing is required for pyrin inflammasome activation in human macrophages and bypassed by mutations causing familial Mediterranean fever. PLoS Biol. 20, e3001351 (2022). · DOI
  15. Minkiewicz, J., de Rivero Vaccari, J. P. & Keane, R. W. Human astrocytes express a novel NLRP2 inflammasome. Glia 61, 1113–1121 (2013). · DOI · Paper page
  16. Hara, H. et al. The NLRP6 inflammasome recognizes lipoteichoic acid and regulates gram-positive pathogen infection. Cell 175, 1651–1664.e14 (2018). · DOI · Paper page
  17. Radian, A. D., Khare, S., Chu, L. H., Dorfleutner, A. & Stehlik, C. ATP binding by NLRP7 is required for inflammasome activation in response to bacterial lipopeptides. Mol. Immunol. 67, 294–302 (2015). · DOI
  18. Sundaram, B. et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell 186, 2783–2801.e20 (2023). · DOI · Paper page
  19. Ravichandran, K. A. & Heneka, M. T. Inflammasome activation in neurodegenerative diseases. Essays Biochem. 65, 885–904 (2021). · DOI
  20. Morrone, S. R. et al. Assembly-driven activation of the AIM2 foreign-dsDNA sensor provides a polymerization template for downstream ASC. Nat. Commun. 6, 7827 (2015). · DOI
  21. Muñoz-Planillo, R. et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142–1153 (2013). · DOI · Paper page
  22. Nakanishi, H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen. Res. 15, 25–29 (2020). · DOI
  23. Duan, T., Du, Y., Xing, C., Wang, H. Y. & Wang, R.-F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 13, 812774 (2022). · DOI · Paper page
  24. Xing, Y. et al. Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome. J. Immunol. 199, 1561–1566 (2017). · DOI · Paper page
  25. Eriksson, I., Wäster, P. & Öllinger, K. Restoration of lysosomal function after damage is accompanied by recycling of lysosomal membrane proteins. Cell Death Dis. 11, 370 (2020). · DOI
  26. Duncan, J. A. et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl Acad. Sci. USA 104, 8041–8046 (2007). · DOI · Paper page
  27. Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407–420 (2016). · DOI · Paper page
  28. Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol. Immunol. 18, 1106–1121 (2021). · DOI · Paper page
  29. Li, Y. et al. Cryo-EM structures of ASC and NLRC4 CARD filaments reveal a unified mechanism of nucleation and activation of caspase-1. Proc. Natl Acad. Sci. USA 115, 10845–10852 (2018). · DOI
  30. Xu, Z. et al. Homotypic CARD-CARD interaction is critical for the activation of NLRP1 inflammasome. Cell Death Dis. 12, 57 (2021). · doi:10.1038/s41419-020-03342-8
  31. Klann, E. M. et al. The gut–brain axis and its relation to Parkinson’s disease: a review. Front. Aging Neurosci. 13, 782082 (2022). · DOI · Paper page
  32. L, K., Ng, T. K. S., Wee, H. N. & Ching, J. Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer’s disease pathology: review and recommendations. Mech. Ageing Dev. 211, 111787 (2023). · DOI
  33. Christ, A. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162–175.e14 (2018). · DOI · Paper page
  34. Hughes, C. et al. Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death. Commun. Biol. 3, 79 (2020). · DOI · Paper page
  35. Ismael, S. et al. ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer’s disease. Neurochem. Int. 148, 105104 (2021). · DOI
  36. Ahmed, M. E. et al. Co-localization of glia maturation factor with NLRP3 inflammasome and autophagosome markers in human Alzheimer’s disease brain. J. Alzheimer’s Dis. 60, 1143–1160 (2017). · DOI
  37. Moonen, S. et al. Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 145, 175–195 (2023). · DOI · Paper page
  38. Tang, H. & Harte, M. Investigating markers of the NLRP3 inflammasome pathway in Alzheimer’s disease: a human post-mortem study. Genes 12, 1753 (2021). · DOI
  39. Tejera, D. et al. Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome. EMBO J. 38, e101064 (2019). · DOI · Paper page
  40. Couturier, J. et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease. J. Neuroinflammation 13, 20 (2016). · DOI
  41. Zhao, Y. et al. NLRP3 inflammasome-dependent increases in high mobility group box 1 involved in the cognitive dysfunction caused by tau-overexpression. Front. Aging Neurosci. 13, 721474 (2021). · DOI
  42. Kumar, S. et al. Role of the caspase-8/RIPK3 axis in Alzheimer’s disease pathogenesis and Aβ-induced NLRP3 inflammasome activation. JCI Insight 8, e157433 (2023). · DOI
  43. Han, C. et al. Double-negative T cells mediate M1 polarization of microglial cells via TNF-α-NLRP3 to aggravate neuroinflammation and cognitive impairment in Alzheimer’s disease mice. J. Cell Physiol. 237, 3860–3871 (2022). · DOI
  44. Rui, W. et al. Systemic inflammasome activation and pyroptosis associate with the progression of amnestic mild cognitive impairment and Alzheimer’s disease. J. Neuroinflammation 18, 280 (2021). · DOI
  45. Mancuso, R. et al. Circulatory miR-223-3p discriminates between Parkinson’s and Alzheimer’s patients. Sci. Rep. 9, 9393 (2019). · DOI
  46. Scott, X. O. et al. The inflammasome adaptor protein ASC in mild cognitive impairment and Alzheimer’s disease. Int. J. Mol. Sci. 21, 4674 (2020). · DOI
  47. Kuwar, R. et al. A novel inhibitor targeting NLRP3 inflammasome reduces neuropathology and improves cognitive function in Alzheimer’s disease transgenic mice. J. Alzheimer’s Dis. 82, 1769–1783 (2021). · DOI
  48. Yin, J. et al. NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease. Mol. Neurobiol. 55, 1977–1987 (2018). · DOI · Paper page
  49. Park, M. H. et al. N,N′-diacetyl-p-phenylenediamine restores microglial phagocytosis and improves cognitive defects in Alzheimer’s disease transgenic mice. Proc. Natl Acad. Sci. USA 116, 23426–23436 (2019). · DOI
  50. Han, S. et al. Effect of increased IL-1β on expression of HK in Alzheimer’s disease. Int. J. Mol. Sci. 22, 1306 (2021). · DOI
  51. Haseeb, M. et al. Novel small-molecule inhibitor of NLRP3 inflammasome reverses cognitive impairment in an Alzheimer’s disease model. ACS Chem. Neurosci. 13, 818–833 (2022). · DOI
  52. Xu, W., Zhang, L., Geng, Y., Liu, Y. & Zhang, N. Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson’s disease by regulating NLRP3 pathway through sponging miR-223-3p. Int. Immunopharmacol. 85, 106614 (2020). · DOI · Paper page
  53. Tan, M.-S., Liu, Y., Hu, H., Tan, C.-C. & Tan, L. Inhibition of caspase-1 ameliorates tauopathy and rescues cognitive impairment in SAMP8 mice. Metab. Brain Dis. 37, 1197–1205 (2022). · DOI · Paper page
  54. Flores, J., Fillion, M.-L. & LeBlanc, A. C. Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice. Cell Death Dis. 13, 864 (2022). · DOI
  55. Hou, Y. et al. NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS–STING. Proc. Natl Acad. Sci. USA 118, e2011226118 (2021). · DOI · Paper page
  56. Španić, E., Langer Horvat, L., Ilić, K., Hof, P. R. & Šimić, G. NLRP1 inflammasome activation in the hippocampal formation in Alzheimer’s disease: correlation with neuropathological changes and unbiasedly estimated neuronal loss. Cells 11, 2223 (2022). · DOI
  57. Reimers, D. et al. Immunohistochemical study of ASC expression and distribution in the hippocampus of an aged murine model of Alzheimer’s disease. Int. J. Mol. Sci. 22, 8697 (2021). · DOI
  58. Zhang, M. et al. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer’s disease by suppressing NLRP2 activation in astrocytes. Mol. Cell Endocrinol. 542, 111529 (2022). · DOI
  59. Cao, L.-L. et al. Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP/PS1 transgenic mice. J. Neuroinflammation 18, 281 (2021). · DOI
  60. Flores, J., Noël, A., Fillion, M.-L. & LeBlanc, A. C. Therapeutic potential of Nlrp1 inflammasome, caspase-1, or caspase-6 against Alzheimer disease cognitive impairment. Cell Death Differ. 29, 657–669 (2022). · DOI
  61. Oronsky, B. et al. REPLATINUM phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 15, 3427–3433 (2019). · DOI
  62. Reid, T., Oronsky, B., Caroen, S. & Cabrales, P. The direct NLRP3 inhibitor and phase 3 small molecule anticancer agent, RRx‐001, protects aged triple transgenic Alzheimer’s disease model mice from CNS degeneration and cognitive decline. Alzheimers Dement. 18 (Suppl. 10), e061516 (2022). · doi:10.1002/alz.061516
  63. Shippy, D. C., Wilhelm, C., Viharkumar, P. A., Raife, T. J. & Ulland, T. K. β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology. J. Neuroinflammation 17, 280 (2020). · DOI · Paper page
  64. Wirianto, M. et al. The clock modulator nobiletin mitigates astrogliosis-associated neuroinflammation and disease hallmarks in an Alzheimer’s disease model. FASEB J. 36, e22186 (2022). · DOI
  65. Deng, Y. et al. AVE 0991 suppresses astrocyte-mediated neuroinflammation of Alzheimer’s disease by enhancing autophagy. J. Inflamm. Res. 16, 391–406 (2023). · DOI
  66. Sun, J. et al. Microbiota-derived metabolite Indoles induced aryl hydrocarbon receptor activation and inhibited neuroinflammation in APP/PS1 mice. Brain Behav. Immun. 106, 76–88 (2022). · DOI · Paper page
  67. Duan, R. et al. Angiotensin-(1–7) analogue AVE0991 modulates astrocyte-mediated neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 pathway and offers neuroprotection in a transgenic mouse model of Alzheimer’s disease. J. Inflamm. Res. 14, 7007–7019 (2021). · DOI
  68. Scheiblich, H. et al. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct α-synuclein assemblies. J. Immunol. 207, 2143–2154 (2021). · DOI · Paper page
  69. Lawrence, G. M., Holley, C. L. & Schroder, K. Parkinson’s disease: connecting mitochondria to inflammasomes. Trends Immunol. 43, 877–885 (2022). · DOI
  70. Hernandez-Baltazar, D., Zavala-Flores, L. M. & Villanueva-Olivo, A. The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurologia 32, 533–539 (2017). · DOI
  71. Sarkar, S. et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. NPJ Parkinsons Dis. 3, 30 (2017). · DOI · Paper page
  72. Wang, X. et al. α-synuclein promotes progression of Parkinson’s disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome. Exp. Ther. Med. 19, 931–938 (2020).
  73. Cao, H., Han, X., Jia, Y. & Zhang, B. Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson’s disease model via targeting miR-124-3p mediated FSTL1/NFκB axis. Aging 13, 11455–11469 (2021). · DOI
  74. Li, Q., Wang, Z., Xing, H., Wang, Y. & Guo, Y. Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Mol. Ther. Nucleic Acids 23, 1334–1344 (2021). · DOI · Paper page
  75. Dong, A. et al. Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease. Acta Pharmacol. Sin. 44, 32–43 (2023). · DOI
  76. Chen, C.-M. et al. Pathomechanism characterization and potential therapeutics identification for Parkinson’s disease targeting neuroinflammation. Int. J. Mol. Sci. 22, 1062 (2021). · DOI
  77. De Nuccio, F. et al. Inflammatory response modulation by vitamin C in an MPTP mouse model of Parkinson’s disease. Biology 10, 1155 (2021). · DOI
  78. Hou, L. et al. Integrin Mac1 mediates paraquat and maneb-induced learning and memory impairments in mice through NADPH oxidase–NLRP3 inflammasome axis-dependent microglial activation. J. Neuroinflammation 20, 42 (2023). · DOI
  79. Chiu, Y.-J. et al. Investigating therapeutic effects of indole derivatives targeting inflammation and oxidative stress in neurotoxin-induced cell and mouse models of Parkinson’s disease. Int. J. Mol. Sci. 24, 2642 (2023). · DOI
  80. Panicker, N. et al. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. J. Exp. Med. 216, 1411–1430 (2019). · DOI · Paper page
  81. von Herrmann, K. M. et al. NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease. NPJ Parkinsons Dis. 4, 24 (2018). · DOI · Paper page
  82. Panicker, N. et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson’s disease. Neuron 110, 2422–2437.e9 (2022). · DOI · Paper page
  83. Javed, H. et al. NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson’s disease. Int. Immunopharmacol. 83, 106441 (2020). · DOI
  84. Anderson, F. L. et al. Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients. NPJ Parkinsons Dis. 7, 2 (2021). · DOI
  85. Roy, A., Choudhury, S., Banerjee, R., Basu, P. & Kumar, H. Soluble LAG-3 and Toll-interacting protein: novel upstream neuro-inflammatory markers in Parkinson’s disease. Parkinsonism Relat. Disord. 91, 121–123 (2021). · doi:10.1016/j.parkreldis.2021.09.019
  86. Cabrera Ranaldi, E. D. L. R. M. et al. Proof-of-principle study of inflammasome signaling proteins as diagnostic biomarkers of the inflammatory response in Parkinson’s disease. Pharmaceuticals 16, 883 (2023). · DOI
  87. Rui, W. et al. Microglial AIM2 alleviates antiviral‐related neuro‐inflammation in mouse models of Parkinson’s disease. Glia 70, 2409–2425 (2022). · DOI
  88. Huang, S. et al. Berberine protects against NLRP3 inflammasome via ameliorating autophagic impairment in MPTP-induced Parkinson’s disease model. Front. Pharmacol. 11, 618787 (2021). · DOI
  89. Ou, Z. et al. NLRP3 inflammasome inhibition prevents α-synuclein pathology by relieving autophagy dysfunction in chronic MPTP-treated NLRP3 knockout mice. Mol. Neurobiol. 58, 1303–1311 (2021). · DOI
  90. Qiao, C. et al. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease. J. Neuroinflammation 15, 193 (2018). · DOI
  91. Shao, Q. et al. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease. Acta Pharmacol. Sin. 40, 1503–1512 (2019). · DOI
  92. Hou, L. et al. Integrin CD11b mediates locus coeruleus noradrenergic neurodegeneration in a mouse Parkinson’s disease model. J. Neuroinflammation 17, 148 (2020). · DOI
  93. Zhang, X. et al. Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis. Aging 12, 9405–9426 (2020). · DOI · Paper page
  94. Zheng, R. et al. ASC specks exacerbate α-synuclein pathology via amplifying NLRP3 inflammasome activities. J. Neuroinflammation 20, 26 (2023). · DOI
  95. Zheng, R. et al. Melatonin attenuates neuroinflammation by down-regulating NLRP3 inflammasome via a SIRT1-dependent pathway in MPTP-induced models of Parkinson’s disease. J. Inflamm. Res. 14, 3063–3075 (2021). · DOI
  96. Jiang, Z. et al. β-Hydroxybutyrate alleviates pyroptosis in MPP+/MPTP-induced Parkinson’s disease models via inhibiting STAT3/NLRP3/GSDMD pathway. Int. Immunopharmacol. 113, 109451 (2022). · DOI
  97. Qiu, J. et al. Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson’s disease model. Neuropharmacology 207, 108963 (2022). · DOI · Paper page
  98. Ahmed, S., Panda, S. R., Kwatra, M., Sahu, B. D. & Naidu, V. G. M. Perillyl alcohol attenuates nlrp3 inflammasome activation and rescues dopaminergic neurons in experimental in vitro and in vivo models of Parkinson’s disease. ACS Chem. Neurosci. 13, 53–68 (2022). · DOI
  99. Liu, Y. et al. Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson’s disease. Acta Pharm. Sin. B 13, 662–677 (2023). · DOI
  100. Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071 (2017). · DOI · Paper page
  101. Masrori, P. & Van Damme, P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 27, 1918–1929 (2020). · DOI · Paper page
  102. Urushitani, M., Kurisu, J., Tsukita, K. & Takahashi, R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 83, 1030–1042 (2002). · DOI · Paper page
  103. Schwenk, B. M. et al. TDP‐43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J. 35, 2350–2370 (2016). · DOI
  104. Higgins, C. M. J., Jung, C. & Xu, Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 4, 16 (2003). · DOI · Paper page
  105. Wang, W. et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 22, 869–878 (2016). · DOI · Paper page
  106. Apolloni, S. et al. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model. Mech. 7, 1101–1109 (2014).
  107. Heitzer, M. et al. Administration of 17β-estradiol improves motoneuron survival and down-regulates inflammasome activation in male SOD1(G93A) ALS mice. Mol. Neurobiol. 54, 8429–8443 (2017). · DOI · Paper page
  108. Hummel, C. et al. Expression and cell type-specific localization of inflammasome sensors in the spinal cord of SOD1(G93A) mice and sporadic amyotrophic lateral sclerosis patients. Neuroscience 463, 288–302 (2021). · DOI
  109. Moreno-García, L. et al. Inflammasome in ALS skeletal muscle: NLRP3 as a potential biomarker. Int. J. Mol. Sci. 22, 288 (2021). · DOI
  110. Zhang, H. et al. Spatiotemporal evolution of pyroptosis and canonical inflammasome pathway in hSOD1G93A ALS mouse model. BMC Neurosci. 23, 50 (2022). · DOI
  111. Van Schoor, E. et al. Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex. Acta Neuropathol. 144, 393–411 (2022). · DOI
  112. Johann, S. et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 63, 2260–2273 (2015). · DOI · Paper page
  113. Cunha, C. et al. Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage. Mol. Neurobiol. 55, 4207–4224 (2018).
  114. Lehmann, S. et al. Expression profile of pattern recognition receptors in skeletal muscle of SOD1(G93A) amyotrophic lateral sclerosis (ALS) mice and sporadic ALS patients. Neuropathol. Appl. Neurobiol. 44, 606–627 (2018). · DOI
  115. Meissner, F., Molawi, K. & Zychlinsky, A. Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis. Proc. Natl Acad. Sci. USA 107, 13046–13050 (2010). · DOI · Paper page
  116. Shu, X. et al. Negative regulation of TREM2-mediated C9orf72 poly-GA clearance by the NLRP3 inflammasome. Cell Rep. 42, 112133 (2023). · DOI
  117. Bartlett, R., Sluyter, V., Watson, D., Sluyter, R. & Yerbury, J. J. P2X7 antagonism using brilliant blue G reduces body weight loss and prolongs survival in female SOD1(G93A) amyotrophic lateral sclerosis mice. PeerJ 5, e3064 (2017). · DOI
  118. Maier, A. et al. Interleukin-1 antagonist anakinra in amyotrophic lateral sclerosis – a pilot study. PLoS ONE 10, e0139684 (2015). · DOI
  119. Dobson, R. & Giovannoni, G. Multiple sclerosis – a review. Eur. J. Neurol. 26, 27–40 (2019). · DOI · Paper page
  120. Ransohoff, R. M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 15, 1074–1077 (2012). · DOI · Paper page
  121. Keane, R. W., Dietrich, W. D. & de Rivero Vaccari, J. P. Inflammasome proteins as biomarkers of multiple sclerosis. Front. Neurol. 9, 135 (2018). · DOI
  122. Hou, B. et al. Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. Cell Death Dis. 11, 377 (2020). · DOI · Paper page
  123. Barclay, W. E. et al. The AIM2 inflammasome is activated in astrocytes during the late phase of EAE. JCI Insight 7, e155563 (2022). · DOI
  124. Noroozi, S., Meimand, H. A. E., Arababadi, M. K., Nakhaee, N. & Asadikaram, G. The effects of IFN-β1a on the expression of inflammasomes and apoptosis-associated speck-like proteins in multiple sclerosis patients. Mol. Neurobiol. 54, 3031–3037 (2017). · DOI
  125. Galloway, D. A. et al. Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelination. J. Neurochem. 163, 94–112 (2022). · DOI
  126. Malhotra, S. et al. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain 143, 1414–1430 (2020). · DOI
  127. Blandford, S. N. et al. Interleukin-1 receptor antagonist: an exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 52, 103006 (2021). · DOI
  128. Soares, J. L. S., Oliveira, E. M. L. & Pontillo, A. Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis. Mult. Scler. Relat. Disord. 29, 26–34 (2019). · DOI
  129. McKenzie, B. A. et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl Acad. Sci. USA 115, E6065–E6074 (2018). · DOI · Paper page
  130. Zhang, Q. et al. TH17 cells promote CNS inflammation by sensing danger signals via Mincle. Nat. Commun. 13, 2406 (2022). · DOI
  131. Inoue, M. et al. Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci. Signal. 5, ra38 (2012). · DOI · Paper page
  132. Zhang, Y. et al. TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia. Cell Death Dis. 12, 1159 (2021). · DOI
  133. Shao, Y. et al. TRPM2 contributes to neuroinflammation and cognitive deficits in a cuprizone-induced multiple sclerosis model via NLRP3 inflammasome. Neurobiol. Dis. 160, 105534 (2021). · DOI
  134. Liu, M. et al. TRPV4 inhibition improved myelination and reduced glia reactivity and inflammation in a cuprizone-induced mouse model of demyelination. Front. Cell Neurosci. 12, 392 (2018). · DOI
  135. Sánchez-Fernández, A., Skouras, D. B., Dinarello, C. A. & López-Vales, R. OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front. Immunol. 10, 2578 (2019). · DOI · Paper page
  136. Guo, C. et al. Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem. Neurosci. 8, 2194–2201 (2017). · DOI
  137. Cao, R. et al. Identification of a small molecule with strong anti-inflammatory activity in experimental autoimmune encephalomyelitis and sepsis through blocking gasdermin D activation. J. Immunol. 209, 820–828 (2022). · DOI
  138. Lang, Y. et al. Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes. Clin. Exp. Immunol. 207, 378–386 (2022). · DOI
  139. Desu, H. L. et al. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis. J. Neuroinflammation 17, 143 (2020). · DOI
  140. Humphries, F. et al. Succination inactivates gasdermin D and blocks pyroptosis. Science 369, 1633–1637 (2020). · DOI · Paper page
  141. Wang, X. et al. Nicotinamide adenine dinucleotide treatment alleviates the symptoms of experimental autoimmune encephalomyelitis by activating autophagy and inhibiting the NLRP3 inflammasome. Int. Immunopharmacol. 90, 107092 (2021). · DOI
  142. Song, S. et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci. Ther. 28, 422–434 (2022). · DOI
  143. Liu, F., Li, Z., He, X., Yu, H. & Feng, J. Ghrelin attenuates neuroinflammation and demyelination in experimental autoimmune encephalomyelitis involving NLRP3 inflammasome signaling pathway and pyroptosis. Front. Pharmacol. 10, 1320 (2019). · DOI
  144. Malhotra, S. et al. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain 138, 644–652 (2015). · DOI
  145. Li, Z., Liu, Y., Jia, A., Cui, Y. & Feng, J. Cerebrospinal fluid cells immune landscape in multiple sclerosis. J. Transl. Med. 19, 125 (2021). · DOI
  146. Campbell, B. C. V. et al. Ischaemic stroke. Nat. Rev. Dis. Prim. 5, 70 (2019). · DOI · Paper page
  147. Yan, J. et al. CCR5 activation promotes NLRP1-dependent neuronal pyroptosis via CCR5/PKA/CREB pathway after intracerebral hemorrhage. Stroke 52, 4021–4032 (2021). · DOI
  148. Sun, X. et al. NLRP2 is highly expressed in a mouse model of ischemic stroke. Biochem. Biophys. Res. Commun. 479, 656–662 (2016). · DOI
  149. Yang-Wei Fann, D. et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 4, e790 (2013). · DOI · Paper page
  150. He, X. et al. Extracellular ASC exacerbated the recurrent ischemic stroke in an NLRP3-dependent manner. J. Cereb. Blood Flow. Metab. 40, 1048–1060 (2019). · DOI
  151. Huang, X. et al. BRCC3 promotes activation of the NLRP6 inflammasome following cerebral ischemia/reperfusion (I/R) injury in rats. Neurosci. Lett. 756, 135954 (2021). · DOI
  152. Li, Z.-G., Shui, S.-F., Han, X.-W. & Yan, L. NLRP10 ablation protects against ischemia/reperfusion-associated brain injury by suppression of neuroinflammation. Exp. Cell Res. 389, 111912 (2020). · DOI
  153. Kim, H. et al. AIM2 inflammasome contributes to brain injury and chronic post-stroke cognitive impairment in mice. Brain Behav. Immun. 87, 765–776 (2020). · DOI · Paper page
  154. Li, J. et al. Caspase-1 inhibition prevents neuronal death by targeting the canonical inflammasome pathway of pyroptosis in a murine model of cerebral ischemia. CNS Neurosci. Ther. 26, 925–939 (2020). · DOI
  155. Li, Q. et al. Correlation between the levels of NLRP3, Hcy, IL-1β, IL-18 and the prognosis in patients with hemorrhagic stroke. Am. J. Transl. Res. 13, 2883–2890 (2021).
  156. Ismael, S., Nasoohi, S., Yoo, A., Ahmed, H. A. & Ishrat, T. Tissue plasminogen activator promotes TXNIP-NLRP3 inflammasome activation after hyperglycemic stroke in mice. Mol. Neurobiol. 57, 2495–2508 (2020). · DOI
  157. Denes, A. et al. AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc. Natl Acad. Sci. USA 112, 4050–4055 (2015). · DOI · Paper page
  158. Mo, Z. et al. Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation. Life Sci. 242, 117133 (2020). · DOI
  159. Zhang, M.-J. et al. The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome. FASEB J. 34, 648–662 (2020). · DOI
  160. Xu, S. et al. AIM2 deletion enhances blood-brain barrier integrity in experimental ischemic stroke. CNS Neurosci. Ther. 27, 1224–1237 (2021). · DOI
  161. Cao, Y. et al. Overexpression of microRNA-9a-5p ameliorates NLRP1 inflammasome-mediated ischemic injury in rats following ischemic stroke. Neuroscience 444, 106–117 (2020). · DOI
  162. Bellut, M. et al. NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood–brain barrier integrity in murine stroke. Cell Death Dis. 13, 20 (2021). · DOI
  163. Ren, H. et al. Selective NLRP3 (pyrin domain-containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage. Stroke 49, 184–192 (2018). · DOI · Paper page
  164. Miao, H. et al. Edaravone administration confers neuroprotection after experimental intracerebral hemorrhage in rats via NLRP3 suppression. J. Stroke Cerebrovasc. Dis. 29, 104468 (2020). · DOI
  165. Pan, L. et al. Novel caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window. Acta Pharmacol. Sin. 43, 2817–2827 (2022). · DOI
  166. Goddard, G. V. Development of epileptic seizures through brain stimulation at low intensity. Nature 214, 1020–1021 (1967). · DOI · Paper page
  167. Friedman, L. et al. Kainate-induced status epilepticus alters glutamate and GABAA receptor gene expression in adult rat hippocampus: an in situ hybridization study. J. Neurosci. 14, 2697–2707 (1994). · DOI · Paper page
  168. Turski, W. A. et al. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behavioural Brain Res. 9, 315–335 (1983). · DOI · Paper page
  169. Velisek, L. et al. Pentylenetetrazol-induced seizures in rats: an ontogenetic study. Naunyn Schmiedebergs Arch. Pharmacol. 346, 588–591 (1992). · DOI
  170. Becker, A. J. Review: animal models of acquired epilepsy: insights into mechanisms of human epileptogenesis. Neuropathol. Appl. Neurobiol. 44, 112–129 (2018). · DOI · Paper page
  171. Wang, Y., Wei, P., Yan, F., Luo, Y. & Zhao, G. Animal models of epilepsy: a phenotype-oriented review. Aging Dis. 13, 215 (2022). · DOI
  172. Pohlentz, M. S. et al. Characterisation of NLRP3 pathway-related neuroinflammation in temporal lobe epilepsy. PLoS ONE 17, e0271995 (2022). · DOI
  173. Samadianzakaria, A., Abdolmaleki, Z. & Faedmaleki, F. The effect of valproic acid and furosemide on the regulation of the inflammasome complex (NLRP1 and NLRP3 mRNA) in the brain of epileptic animal model. Brain Res. Bull. 191, 20–29 (2022). · DOI
  174. Tan, C.-C. et al. NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model. J. Neuroinflammation 12, 18 (2015). · DOI · Paper page
  175. Meng, X.-F. et al. Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus. J. Neuroinflammation 11, 212 (2014). · DOI
  176. Yue, J. et al. NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: molecular insights into their interdependence. Neuropathol. Appl. Neurobiol. 46, 770–785 (2020). · DOI
  177. Yue, J. et al. Decreased expression of Rev-Erbα in the epileptic foci of temporal lobe epilepsy and activation of Rev-Erbα have anti-inflammatory and neuroprotective effects in the pilocarpine model. J. Neuroinflammation 17, 43 (2020). · DOI
  178. Shen, J. et al. TRPV4 channels stimulate Ca2+-induced Ca2+ release in mouse neurons and trigger endoplasmic reticulum stress after intracerebral hemorrhage. Brain Res. Bull. 146, 143–152 (2019). · DOI
  179. Jimenez-Pacheco, A. et al. Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy. J. Neurosci. 36, 5920 (2016). · DOI · Paper page
  180. Wang, X. et al. DHA and EPA prevent seizure and depression-like behavior by inhibiting ferroptosis and neuroinflammation via different mode-of-actions in a pentylenetetrazole-induced kindling model in mice. Mol. Nutr. Food Res. 66, 2200275 (2022). · DOI
  181. Qin, Z. et al. GPR120 modulates epileptic seizure and neuroinflammation mediated by NLRP3 inflammasome. J. Neuroinflammation 19, 121 (2022). · DOI
  182. Brito Toscano, E. C.de et al. NLRP3 and NLRP1 inflammasomes are up-regulated in patients with mesial temporal lobe epilepsy and may contribute to overexpression of caspase-1 and IL-β in sclerotic hippocampi. Brain Res. 1752, 147230 (2021). · DOI
  183. Morin-Brureau, M. et al. Microglial phenotypes in the human epileptic temporal lobe. Brain 141, 3343–3360 (2018). · DOI
  184. Tröscher, A. R. et al. Microglial nodules provide the environment for pathogenic T cells in human encephalitis. Acta Neuropathol. 137, 619–635 (2019). · DOI
  185. Maroso, M. et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16, 413–419 (2010). · DOI · Paper page
  186. Ulusoy, C. et al. Peripheral blood expression levels of inflammasome complex components in two different focal epilepsy syndromes. J. Neuroimmunol. 347, 577343 (2020). · DOI
  187. DeSena, A. D., Do, T. & Schulert, G. S. Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J. Neuroinflammation 15, 38 (2018). · DOI
  188. Dewan, M. C. et al. Estimating the global incidence of traumatic brain injury. J. Neurosurg. 130, 1080–1097 (2019). · DOI · Paper page
  189. Bodnar, C. N., Roberts, K. N., Higgins, E. K. & Bachstetter, A. D. A systematic review of closed head injury models of mild traumatic brain injury in mice and rats. J. Neurotrauma 36, 1683–1706 (2019). · DOI · Paper page
  190. Sun, Z. et al. VX765 attenuates pyroptosis and HMGB1/TLR4/NF-κB pathways to improve functional outcomes in TBI mice. Oxid. Med. Cell Longev. 2020, 7879629 (2020). · DOI
  191. Ge, X. et al. The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury. Brain Res. 1697, 10–20 (2018). · DOI
  192. Adamczak, S. E. et al. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J. Cereb. Blood Flow. Metab. 34, 621–629 (2014). · DOI · Paper page
  193. Kerr, N. et al. Inflammasome proteins as biomarkers of traumatic brain injury. PLoS ONE 13, e0210128 (2019). · DOI
  194. Johnson, N. H. et al. Inflammatory biomarkers of traumatic brain injury. Pharmaceuticals 15, 660 (2022). · DOI
  195. Lin, C. et al. Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury. Exp. Neurol. 290, 115–122 (2017). · DOI
  196. Wu, L. et al. Repetitive mild closed head injury in adolescent mice is associated with impaired proteostasis, neuroinflammation, and tauopathy. J. Neurosci. 42, 2418 (2022). · DOI
  197. Du, H., Li, C.-H., Gao, R.-B., Cen, X.-Q. & Li, P. Ablation of GSDMD attenuates neurological deficits and neuropathological alterations after traumatic brain injury. Front. Cell Neurosci. 16, 915969 (2022). · DOI
  198. Irrera, N. et al. Lack of the Nlrp3 inflammasome improves mice recovery following traumatic brain injury. Front. Pharm. 8, 459 (2017). · DOI
  199. Tan, S.-W. et al. HMGB1 mediates cognitive impairment caused by the NLRP3 inflammasome in the late stage of traumatic brain injury. J. Neuroinflammation 18, 241 (2021). · DOI
  200. Lopez-Rodriguez, A. B. et al. Activation of NLRP3 is required for a functional and beneficial microglia response after brain trauma. Pharmaceutics 14, 1550 (2022). · DOI

200 of 237 shown

Cited by

See all 117

Metadata

Authors
Ravichandran, K. A., & Heneka, M. T.
Venue
Nature Reviews Neurology
Published
2024-01-09
Volume
20
Issue
2
Pages
67-83
ISSN
  • 1759-4758
  • 1759-4766
Cited by
117
References
60
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammasomes in neurological disorders — mechanisms and therapeutic potential. https://app.cochat.ai/papers/10.1038/s41582-023-00915-x
The paper
Ravichandran, K. A., & Heneka, M. T. (2024). Inflammasomes in neurological disorders — mechanisms and therapeutic potential. Nature Reviews Neurology. https://doi.org/10.1038/s41582-023-00915-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.